Results 191 to 200 of about 31,387 (227)

Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma. [PDF]

JCO Precis Oncol
Gupta S, Lee JK, Mitchell J, Huang RSP.
europepmc   +1 more source

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis in Metastatic Urothelial Carcinoma Complicated by Severe Gastrointestinal Bleeding. [PDF]

IJU Case Rep
Matsuyama A, Kato T, Kawase R, Kobayashi M, Momota A, Tsunoda Y, Yamaguchi A, Hirabayashi H, Suzuki S, Kato M.   +9 more
europepmc   +1 more source

Brain metastasis in a patient with metastatic urothelial carcinoma after 7 years of avelumab maintenance therapy: A case report. [PDF]

Urol Case Rep
Aagaard KA, Einarsson HB, Hjulskov SH, Simonsen MTF, Carus A.   +4 more
europepmc   +1 more source

Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study. [PDF]

Oncologist
Odagiri K, Mimura Y, Naiki T, Tasaki Y, Sugiyama Y, Naiki-Ito A, Etani T, Nagai T, Morikawa T, Shimizu N, Aoki M, Gonda M, Yasui T, Furukawa-Hibi Y.   +13 more
europepmc   +1 more source

Association between antibiotics and treatment efficacy in metastatic urothelial carcinoma patients. [PDF]

BMC Med
Braun A, Deng M, Hasler JS, Bukavina L, Handorf E, Abbosh PH.   +5 more
europepmc   +1 more source

Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma. [PDF]

ESMO Open
Sternschuss M, Toumbacaris N, Das JP, Powles T, Kotecha RR, Laccetti AL, Xiao H, Feld E, McHugh DJ, Keegan NM, Bajorin DF, Funt SA, Shah NJ, Iyer G, Aggen DH, Teo MY, Ostrovnaya I, Rosenberg JE.   +17 more
europepmc   +1 more source

A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma. [PDF]

Target Oncol
Grivas P, Moon HH.
europepmc   +1 more source

Factors associated with primary resistance to enfortumab vedotin in previously treated patients with metastatic urothelial carcinoma: a multicenter retrospective study. [PDF]

Int J Clin Oncol
Ikarashi D, Hayakawa N, Kaneko G, Sakura Y, Endo Y, Yamashita R, Shirotake S, Kondo Y, Kikuchi E, Obara W.   +9 more
europepmc   +1 more source

Successful Management of Tumor Lysis Syndrome Following Enfortumab Vedotin Plus Pembrolizumab Therapy in Metastatic Urothelial Carcinoma: A Case Report. [PDF]

IJU Case Rep
Takemori D, Shigehisa R, Shimasaki S, Yamashita E, Kurano Y, Atagi K, Ota Y, Yamamoto S, Osakabe H, Nao T, Shimamoto T, Fukuhara H, Shimizu N, Fukata S, Ashida S, Inoue K.   +15 more
europepmc   +1 more source

Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France. [PDF]

Future Oncol
Joly F, Culine S, Roupret M, Tricotel A, Casarotto E, Brice S, Minacori R, Vuillet M, Thomas MC, Leyland K, Upadhyay A, Munro V, Strunz-McKendry T.   +12 more
europepmc   +1 more source